Zepbound KwikPen self-pay pricing reaches pharmacies nationwide

Eli Lilly said on March 16, 2026 that self-pay pricing for the Zepbound (tirzepatide) single-patient-use KwikPen is now available at major pharmacies nationwide, not just through the company's own LillyDirect pharmacy, starting at $299 a month for the 2.5 mg dose ^[1][3].

The mechanism is a new KwikPen Self-Pay Savings Card, posted at zepbound.lilly.com/savings. Lilly says the card is available to all patients, including people with no insurance coverage, and that adults with a valid, on-label prescription for the Zepbound KwikPen can use it to get the same self-pay prices LillyDirect offers ^[1]. The card applies only to the KwikPen. It does not apply to Zepbound single-dose vials or the single-dose pen ^[1].

What the prices actually are

According to Lilly's terms and conditions, the card lets a self-paying patient pay as low as $299 for a one-month fill of the 2.5 mg KwikPen, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg or 15 mg ^[2]. The $449 price on the higher doses comes through the Zepbound Self Pay Journey Program, which requires refilling within 45 days of the delivery or receipt date of the previous prescription ^[2].

Miss that 45-day window and the regular self-pay price applies: $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg and 15 mg ^[2]. In other words, the difference between refilling on schedule and refilling late can be $250 a month at the top doses.

Some other details matter. A "month" is defined as 28 days and one KwikPen, which holds four weekly doses ^[2]. The card can be used for a maximum of 11 fills per calendar year, and it expires on 12/31/2026 ^[2]. Savings are capped per month — up to $215 on 2.5 mg, $115 on 5 mg, $65 on 7.5 mg, and $271 on 10 mg, 12.5 mg and 15 mg ^[2]. Taxes and fees may apply ^[2].

Eligibility rules are specific: you must be 18 or older, a resident of the United States or Puerto Rico, have a prescription consistent with FDA-approved labeling, and agree that the card is for cash-paying patients only. You cannot seek reimbursement from private insurance or any state or federal health program, or apply the cost toward a deductible or true out-of-pocket total ^[2]. Lilly also warns that savings may not be applied at the register and may require further action from the patient to obtain, through a post-transaction reimbursement process ^[2].

Why it matters for patients

For people paying cash, the practical change is choice of pharmacy. Until now, the lowest advertised Zepbound self-pay prices ran through LillyDirect home delivery; the card extends those prices to retail counters, so a prescription can be picked up locally instead ^[1][3].

The pricing tiers also make the cost of dose escalation concrete. Starting at 2.5 mg costs $299 a month, while the maintenance doses Lilly lists on the label — 5 mg, 10 mg or 15 mg weekly for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea — land at $399 or $449 under the program, or up to $699 without the refill offer ^[1][2].

The exclusions are just as important. If your prescription is written for a vial or a single-dose pen, this card does not help ^[1]. And the program is separate from insurance-based savings: Lilly's provider page lists a separate card for eligible commercially insured patients starting at $25 a month for the single-dose pen, with government beneficiaries excluded, and notes some Medicare Part D beneficiaries may pay no more than $50 a month under Medicare GLP-1 Bridge clinical criteria ^[2].

What happens next

On April 9, 2026, GoodRx announced it was offering self-pay pricing for the Zepbound KwikPen starting at $299 a month across more than 70,000 pharmacies nationwide, alongside Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149 a month ^[4].

The savings card and its listed prices end 12/31/2026, and Lilly says it can terminate, revoke or amend the terms at any time, without notice, for any reason ^[2]. Whether comparable pricing continues into 2027 is not yet known from these announcements.